30 November 2017

Beximco Pharma wins Best Company in an Emerging Market at the 2017 Scrip Awards

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that the Company has won the award for the ’Best Company in an Emerging Market’ at the Scrip Awards, presented in London, England, on 29 November 2017. Rabbur Reza, Chief Operating Officer of Beximco Pharma, accepted the award on behalf of the Company.

In its 13th year, the Scrip Awards programme recognises the key roles that pharmaceutical, biotech and other related industries play in improving healthcare around the world. The awards provide the industry with an opportunity to acknowledge its highest achievers across all parts of the value chain and to recognise both corporate and individual achievement. A panel of 16 highly respected and independent judges from across diverse sectors evaluated the award entries to select the finalists.

Beximco Pharma Managing Director, Mr Nazmul Hassan MP, commented:
“I am honoured and excited that Beximco Pharma has been selected as the ‘Best Company in an Emerging Market’ at the prestigious Scrip Awards. As a Company that is currently exporting products to over 50 countries and producing more than 500 products encompassing broad therapeutic categories, Beximco Pharma is continuing to expand its reach and impact around the world. As the only Company in Bangladesh to export pharmaceutical products to the US, we are setting a high standard for the pharmaceutical industry in Bangladesh. I look forward to our continued advancement as we strengthen our research and development capabilities, create new partnerships and build our presence in both domestic and international markets.”

For further information please visit or enquire to:

Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, ext.20080

Md. Asad Ullah, FCS, Executive Director & Company Secretary
Tel; +880 2 58611891, +880 2 58612040, Ext 10140

SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 / 3555

Northland Capital Partners Limited (Broker)
Gerry Beaney / Tom Price
Tel: +44 (0)20 3861 6625

FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0)20 3727 1000

Notes to Editors:
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. Ensuring access to quality medicines is the powerful aspiration that motivates 3,500 employees of the Company.

Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in South East Asia, including Singapore, Thailand, Taiwan, Malaysia, Indonesia, Philippines and Hong Kong; Africa, including South Africa, Mauritius, Kenya, Ghana, Ethiopia, Uganda and Nigeria; Central Asia, including Azerbaijan; Middle East, including Kuwait and Jordan; Pacific Island countries; Latin and Central American countries; Europe, including Austria, Germany and Romania; Australia and North America, including the USA and Canada.